Alnylam Pharmaceuticals, Inc. has announced the U.S. Food and Drug Administration (FDA) approval of the supplemental new drug application (SNDA) for its RNAi therapeutic, Amvuttra® (vutrisiran). This ...

Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...

Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

In one study, Alnylam Pharmaceuticals' Amvuttra helped lower the risk of death and heart problems by 28% over three years compared to a placebo. The drug is given as a shot every three months.

The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to treat transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a disease in which harmful proteins build up ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...

MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of people. The drug, called ...